Smartphones may soon be able to add one more entry to their rolodex of skills: the ability to act as a tool to measure blood glucose levels for those suffering from Type 1 diabetes.
After 20 years of research, University of Virginia School of Medicine researchers are in the final testing phases of a system that can automatically measure and monitor blood sugar levels. Early testing produced promising results. Now, researchers say actual patient testing is going well, and the system is circling the landing towards completion.
The app—called “InControl”—can control everything people with diabetes need, eliminating the need for finger pricks and manual insulin injections. This ease of the system could prove to be a game-changer in the lives of 1.25 million people who suffer from the disease.
Effortlessly manages levels
The so-called “artificial pancreas” has been in the works since 2006, says lead researcher Boris Kovatchev, director of the Centre for Diabetes Technology in the US.
Kovatchev’s own father suffered from diabetes, so he saw firsthand the need for an easier way to live with the disease. “We show that it is not only possible, but it can run on a smartphone,” says Kovatchev.
Every five minutes, the system will report blood glucose level results to the app on a nearby android smartphone. It will analyze the data, and if necessary, adjust insulin levels on a small, wearable insulin pump.
Wirelessly controls pump
The app works by controlling an insulin pump: a device which is already used by approximately 350,000 diabetes sufferers in the US. The pump works by delivering user-adjusted doses of insulin to the bloodstream through a very fine needle; it can be worn discreetly under an article of clothing or hooked to a belt.
The wireless monitor, which talks to the pump, is as tiny as a flash drive and can be worn anywhere on the body. Together, the two devices create a digital treatment ecosystem of sorts that can handle the burden of the disease.
"It runs on a five-minute cycle and takes information from these devices and calculates the next best option for the patient pretty much any point in time,” said Chad Rogers, the CEO of TypeZero Technologies, which has licensed and refined the technology.
Final phases of testing
The ultimate goal is to make managing Type 1 diabetes automatic and effortless.
“If it is working, you do not know that it is there,” says Francis Doyle III, dean of Harvard’s Paulson School of Engineering and Applied Sciences, who is collaborating with Kovatchev on the system
UVA researchers have brought the system to nine locations across the U.S. and Europe to try it on 240 patients. Researchers hope to have the trials complete and the system perfected in four years.